Dullens H F, Vuist W, Van der Maas M, Den Otter W
Cancer Immunol Immunother. 1986;23(2):113-8. doi: 10.1007/BF00199816.
DBA/2 mice were immunized i.p. against syngeneic SL2 lymphosarcoma cells. At various days after the last immunization peritoneal and spleen lymphocytes were collected. The lymphocyte suspensions were enriched for T-cells by nylon wool filtration. The peritoneal T-cells from immunized mice (a) expressed direct specific antitumor cytotoxicity in vitro, (b) induced macrophage cytotoxicity in vitro, and (c) exerted tumor neutralization measured in a Winn-type assay. Spleen T-cells from these immunized mice (a) expressed no direct specific antitumor cytotoxicity in vitro, (b) only induced moderate macrophage cytotoxicity in vitro, but (c) exerted tumor neutralization in a Winn assay. For effective tumor neutralization in vivo effector target cell ratios of 1000:1 were required. When the effector/target ratio of 1000:1 was maintained but the absolute numbers of effector and target cells were lowered from 10(6) to 10(5) lymphocytes and 10(3) to 10(2) target cells respectively, no tumor neutralization was obtained. The major effect of the sensitized-transferred T-lymphocytes seemed to be the induction of cytotoxic macrophages in the (naive) recipient mice, as the peritoneal macrophages collected from the recipient mice 7 days after i.p. injection of a mixture of sensitized T-cells and tumor cells were cytotoxic. Purified peritoneal T-lymphocytes collected from these recipient mice were able to induce macrophage cytotoxicity in vitro but expressed no cytotoxic T-cell activity. In conclusion, our results show that in the tumor system used, tumor neutralization after transfer of sensitized lymphocytes is not dependent on the presence of cytotoxic T-lymphocytes. Lymphocytes with the strongest potency to render macrophages cytotoxic (in vitro and in vivo) also induce the best tumor neutralization in vivo, suggesting an important role for host macrophages as antitumor effector cells.
将DBA/2小鼠经腹腔注射免疫,以对抗同基因的SL2淋巴肉瘤细胞。在最后一次免疫后的不同天数,收集腹腔和脾脏淋巴细胞。通过尼龙毛过滤使淋巴细胞悬液富含T细胞。来自免疫小鼠的腹腔T细胞:(a) 在体外表现出直接的特异性抗肿瘤细胞毒性;(b) 在体外诱导巨噬细胞细胞毒性;(c) 在Winn型试验中表现出肿瘤中和作用。来自这些免疫小鼠的脾脏T细胞:(a) 在体外未表现出直接的特异性抗肿瘤细胞毒性;(b) 在体外仅诱导中等程度的巨噬细胞细胞毒性;(c) 在Winn试验中表现出肿瘤中和作用。为了在体内实现有效的肿瘤中和,效应细胞与靶细胞的比例需要达到1000:1。当维持1000:1的效应细胞/靶细胞比例,但效应细胞和靶细胞的绝对数量分别从10⁶降低到10⁵淋巴细胞以及从10³降低到10²靶细胞时,未获得肿瘤中和作用。致敏转移的T淋巴细胞的主要作用似乎是在(未致敏的)受体小鼠中诱导细胞毒性巨噬细胞,因为在腹腔注射致敏T细胞和肿瘤细胞的混合物7天后,从受体小鼠收集的腹腔巨噬细胞具有细胞毒性。从这些受体小鼠收集的纯化腹腔T淋巴细胞能够在体外诱导巨噬细胞细胞毒性,但未表现出细胞毒性T细胞活性。总之,我们的结果表明,在所使用的肿瘤系统中,致敏淋巴细胞转移后的肿瘤中和不依赖于细胞毒性T淋巴细胞的存在。在体外和体内使巨噬细胞具有最强细胞毒性能力的淋巴细胞,在体内也能诱导最佳的肿瘤中和作用,这表明宿主巨噬细胞作为抗肿瘤效应细胞具有重要作用。